Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Agenus Inc.

< Previous 1 2 3 4 Next >

Agenus to Participate in Upcoming September Investor Conferences

August 31, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

August 28, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

August 26, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

August 06, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus to Provide Second Quarter 2026 Financial Report and Development Update

July 28, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026

July 17, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

July 13, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

July 06, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

June 25, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Announces Virtual 2026 Annual Shareholders Meeting

June 02, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

May 21, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

May 21, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

May 15, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

May 11, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

April 21, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

April 17, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

April 03, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

April 01, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

March 26, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

March 16, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

March 10, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab

January 21, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus to Host First 2026 Stakeholder Webcast

January 20, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

January 15, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

January 12, 2026

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

December 23, 2025

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

November 19, 2025

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC

November 18, 2025

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

November 10, 2025

From Agenus Inc.

Via Business Wire

Tickers AGEN

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

November 05, 2025

From Agenus Inc.

Via Business Wire

Tickers AGEN

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.